In addition, a report using surgical specimens successfully converted after lenvatinib treatment showed that the number of CD8-positive T cells (especially Granzyme K/CD8-positive T cells) was significantly higher in tumor samples after lenvatinib treatment than in the control [15]. The gene discussed is CD8A; the disease is neoplasm.